07:00 , May 27, 2013 |  BioCentury  |  Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
07:00 , Aug 23, 2010 |  BC Week In Review  |  Company News

Bio-Gal Ltd., XTL deal

XTL acquired the assets of cancer company Bio-Gal for 133 million newly issued XTL shares valued at $18.6 million based on XTL's close of $0.14 on Aug. 2, before the deal was completed. The deal...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Company News

Bio-GAL Ltd., XTL deal

XTL acquired from Bio-GAL exclusive, worldwide rights to a patent covering the use of recombinant erythropoietin for multiple myeloma (MM) in exchange for about a 50% ownership stake in XTL. Based on XTL's March 17...